MARKET

AKESF

AKESF

Akeso
OTCPK
10.65
NaN%
Closed 09:30 10/23 EDT
OPEN
--
PREV CLOSE
11.58
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
19.49
52 WEEK LOW
10.50
MARKET CAP
10.02B
P/E (TTM)
-68.2692
1D
5D
1M
3M
1Y
5Y
1D
Summit initiates, opens of trial sites of Phase II study of ivonescimab
TipRanks · 6d ago
Akeso Raises HK$1.94 Billion Through Institutional Share Placing
TipRanks · 10/16 09:24
Akeso to Raise HK$1.94 Billion via Discounted Share Placing
TipRanks · 10/13 22:37
Akeso announces first patient dosed in Phase III study of cadonilimab
TipRanks · 10/11 19:10
Akeso, Inc. (9926) Receives a Hold from Bernstein
TipRanks · 10/10 00:25
UBS Sticks to Its Buy Rating for Akeso, Inc. (9926)
TipRanks · 10/01 00:25
Chinese biopharma stocks rally as U.S. signals openness to drug licensing
Seeking Alpha · 09/21 09:37
HSBC Sticks to Its Buy Rating for Akeso, Inc. (9926)
TipRanks · 09/18 00:25
More
About AKESF
Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.

Webull offers Akeso Inc stock information, including OTCPK: AKESF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKESF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKESF stock methods without spending real money on the virtual paper trading platform.